Latest news articles

Added 2 days ago Drug news

CHMP recommends approval of Mayzent in secondary progressive multiple sclerosis.- Novartis

Novartis announced the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion...

Added 15 days ago Drug news

EMA PRAC recommends restrictions on use of Lemtrada in multiple sclerosis.- Sanofi

EMA’s safety committee (PRAC) has recommended restrictions on the use of Lemtrada (alemtuzumab), from Sanofi, in patients with relapsing remitting...

Added 18 days ago Drug news

FDA approves Vumerity for relapsing forms of multiple sclerosis.- Biogen + Alkermes

Biogen Inc and Alkermes announced that the FDA approved Vumerity (diroximel fumarate), a novel oral fumarate with a distinct chemical...

Search all news articles for Multiple sclerosis

Learning Zones

An Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

EPNS 2019 Congress Highlights

EPNS 2019 Congress Highlights

The team is creating daily reports from the 13th European Paediatric Neurology Society (EPNS) Congress, held in Athens, Greece from 17th to 21st September 2019, to bring you coverage of cutting-edge science and advances in clinical care across all fields of paediatric neurology. 

Migraine Knowledge Centre

Migraine Knowledge Centre

The Migraine Knowledge Centre features latest research on the prevalence and impact of migraine, the proposed neurological basis of the condition (and how this is being translated into new and exciting drug therapies), as well as current patient care strategies collated from headache organisations worldwide.

Load more


Multiple sclerosis in adults: management

This guideline covers diagnosing and managing multiple sclerosis in people aged 18 and over. It aims to improve the quality of life for adults with multiple sclerosis by promoting symptom management...

Added 5 years ago

Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis

This 2015 revised guideline replaces former versions. It includes all newly approved or licensed treatments for MS and represents a consensus concerning their use.

Added 4 years ago

Urinary incontinence in neurological disease: assessment and management

This guideline covers assessing and managing urinary incontinence in children, young people and adults with neurological disease.

Added 7 years ago

Search all guidelines for Multiple sclerosis

Journal articles

Cannabis and multiple sclerosis.

Patients with multiple sclerosis have long turned to complementary therapies to manage symptoms that licensed products can only partially control. Around half of patients with multiple sclerosis admit to previous or current cannabis use...

Added 1 month ago

Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis.

Background and purpose: Breakthrough disease on first‐line injectables in relapsing‐remitting multiple sclerosis (RRMS) is a common clinical situation where comparative studies between different escalation therapies are lacking.

Added 1 month ago

Role of B cells and antibodies in multiple sclerosis.

Multiple sclerosis (MS) is a chronically progressive auto-immune mediated inflammatory demyelinating disease of the central nervous system (CNS) which manifests as disturbances in sensorimotor function and cognitive impairment.

Added 1 month ago

Search all journal articles for Multiple sclerosis

Clinical trials

Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) in Relapsing Multiple Sclerosis (RMS)

The primary objectives of the study are to evaluate the safety of BIIB061 versus placebo in participants with Relapsing Multiple Sclerosis (RMS), and to evaluate the efficacy of BIIB061 to improve disability outcome versus placebo...

Added 1 month ago

A Study of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis

This 2-year study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) effects of ocrelizumab in children and adolescents ages >/= 10 to < 18 years with relapsing-remitting multiple sclerosis (RRMS).

Added 1 month ago

A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis

This study will evaluate the safety, tolerability, and descriptive efficacy of BIIB017 in pediatric participants with relapsing-remitting multiple sclerosis (RRMS) and to assess the pharmacokinetics (PK) of BIIB017 in pediatric participants...

Added 5 months ago

Search all clinical trials for Multiple sclerosis


Multiple sclerosis: clinical review

Accrediting body
MIMS Learning - Monthly Index of Medical Specialities
Credits available
Registration required
Subscription fee
Search all CME for Multiple sclerosis